Discover more with less. Unmatched specificity and sensitivity deliver translational insights from 1µl of sample.Uppsala, Sweden, Sept. 19, 2023 Announcing the Olink® Target 48 Mouse Cytokine.
Uppsala, Sweden, Sept. 12, 2023 (GLOBE NEWSWIRE) Eurofins Genomics adopts Olink® technology to advance proteomics research and accelerate precision medicine programs UPPSALA, Sweden, 12th September, 2023 (GLOBE NEWSWIRE) Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK) today announced the collaboration with Eurofins Genomics to bolster its offerings in the fields of research, population health, and regulated clinical trials through the application of Olink technology. The Olink platform rep
UPPSALA, Sweden, Aug. 29, 2023 (GLOBE NEWSWIRE) Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK), today announced that Company management will participate in the following investor events: Goldman Sachs 20th Annual European Medtech and Healthcare Services ConferenceThursday, September 7th at 7:15 am ET Morgan Stanley 21st Annual Global Healthcare ConferenceTuesday, September 12th at 1:35 pm ET A live and archived webcast of the Morgan Stanley fireside chat will be available on the “Events” sec
UPPSALA, Sweden, Aug. 09, 2023 (GLOBE NEWSWIRE) Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK) today announced its unaudited financial results for the second quarter ended June 30, 2023.
UPPSALA, Sweden, Aug. 08, 2023 Olink Holding AB today announced that the Baylor College of Medicine Human Genome Sequencing Center has selected the Olink Explore platform as a proteomics.